SCHEMBL1305355

SCHEMBL1305355

CC(COc1ccc(NC(N)=O)cc1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.62
▸ GLA P06280 1/20 0.58
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.48
▸ MAPT P10636 3/20 0.47
▸ GAA P10253 1/20 0.47
▸ GFER P55789 1/20 0.47
▸ TSHR P16473 2/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ CYP1A2 P05177 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ LTA4H P09960 2/20 0.47
▸ ADRB2 P07550 1/20 0.47
▸ ADRB1 P08588 1/20 0.47
▸ ADRB3 P13945 1/20 0.47
▸ OPRK1 P41145 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27931850 0.84 ALDH1A1 (0.66) ALDH1A1GLANPC1RAB9ASMN1; SMN2
SCHEMBL27916978 0.84 ALDH1A1 (0.66) ALDH1A1GLANPC1RAB9ASMN1; SMN2
SCHEMBL27917022 0.84 ALDH1A1 (0.66) ALDH1A1GLANPC1RAB9ASMN1; SMN2
SCHEMBL8413163 0.80 ALDH1A1 (0.64) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL787523 0.79 TDP1 (0.49) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL1304687 0.78 ALDH1A1 (0.67) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL8413303 0.78 ALDH1A1 (0.51) ALDH1A1RAB9ASMN1; SMN2MAPTGAA
SCHEMBL14307663 0.77 ADRB2 (0.78) GLAMAPTTSHRMEN1CYP1A2
SCHEMBL14977426 0.77 L3MBTL1 (0.62) GAA
SCHEMBL14977512 0.77 L3MBTL1 (0.62) GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048896-B2 Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors Cell Viable Corporation (US) 2011-11-01 — — US claimed
US-8053449-B2 Method for inhibiting AGE complex formation Cell Viable Corporation (US) 2011-11-08 — — US disclosed
US-8048896-B2 Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors Cell Viable Corporation (US) 2011-11-01 — — US disclosed
US-20080076804-A1 METHODS FOR INHIBITING AND BREAKING AGE COMPLEX FORMATION Cell Viable Corporation 2008-03-27 — — US disclosed
US-20070099966-A1 Device and Method for Inhibiting AGE Complex Formation Cell Viable Corporation 2007-05-03 — — US disclosed
EP-1165064-B1 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) HOPE CITY (US) 2004-02-25 — — EP disclosed
US-6337350-B1 CROSSLINKING INHIBITION OF PROTEINS CITY OF HOPE 2002-01-08 — — US disclosed
EP-1165064-A2 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) City of Hope (US) 2002-01-02 — — EP disclosed
WO-2000059875-A2 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) CITY OF HOPE (US) 2000-10-12 — — WO disclosed
Send feedback